DRD1 and glioblastoma: In this context, it was recently shown that DRD1 agonist treatment led to an inhibition of auto-lysosomal degradation in GBM cells and that this process was calcium overload dependent and related to an inhibition of the mammalian target of rapamycin (mTOR) [44].